Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Finding a perfect donor match is a hurdle many blood cancer patients never clear — but a new study offers a promising workaround. A phase 2 trial found that using posttransplant cyclophosphamide (PTCy) as GVHD prophylaxis in mismatched unrelated donor transplants yielded nearly 80% one-year survival with low rates of severe GVHD. The findings could significantly broaden transplant access, especially for patients from diverse ancestral backgrounds.
Finding a perfectly matched bone marrow donor is a challenge many patients with blood cancers never overcome — but a new study suggests a workaround that could change that. A multicenter phase 2 trial of 193 adults showed that using posttransplant cyclophosphamide (PTCy) as GVHD prophylaxis after mismatched unrelated donor (MMUD) transplants produced strong outcomes, even when donor-recipient HLA matching was imperfect. Researchers say this approach could meaningfully expand access to hematopoietic cell transplantation (HCT) for patients who currently have no viable donor options.
The trial enrolled patients with hematologic malignancies who lacked a fully matched donor and required reduced-intensity or non-myeloablative conditioning. Donors ranged from 7/8 to 4/8 HLA matches, and outcomes were notably similar across matching levels — suggesting that even less-than-ideal matches can work with the right GVHD prevention strategy.
By the Numbers:
Why it matters: Many patients — particularly those from non-European ancestries — struggle to find HLA-matched donors. This study demonstrates that PTCy-based GVHD prophylaxis can make mismatched unrelated donor transplants a viable option, potentially offering a life-saving procedure to thousands of patients who would otherwise have none.
